Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 146 (1), 45-9

Double-blind Trial of Imipramine in Alzheimer's Disease Patients With and Without Depression

Affiliations
Clinical Trial

Double-blind Trial of Imipramine in Alzheimer's Disease Patients With and Without Depression

B V Reifler et al. Am J Psychiatry.

Abstract

The authors divided 61 subjects with primary degenerative dementia of the Alzheimer's type into a group who also met DSM-III criteria for depression (N = 28) and a group who did not (N = 33). Both groups were randomly assigned to an 8-week double-blind trial of imipramine or placebo. Scores on the Hamilton Rating Scale for Depression, administered at baseline and weeks 2, 4, 6, and 8, indicated significant improvement in both groups. Two measures of cognitive function yielded differing results. The results suggest that moderate depression is a treatable condition in patients with Alzheimer's disease.

Comment in

Similar articles

See all similar articles

Cited by 38 articles

See all "Cited by" articles

Publication types

Feedback